Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis

Published:2021-09 Issue: Volume:99 Page:102242
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Mori Keiichiro^ORCID,Pradere Benjamin,Quhal Fahad^ORCID,Katayama Satoshi,Mostafaei Hadi,Laukhtina Ekaterina^ORCID,Schuettfort Victor M.,D'Andrea David^ORCID,Egawa Shin,Bensalah Karim,Schmidinger Manuela,Powles Thomas,Shariat Shahrokh F.

Funder

Uehara Memorial Foundation

European Association of Urology

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference42 articles.

1. Updated european association of urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma;Bedke;Eur Urol,2021

2. The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis;Mori;Eur Urol,2020

3. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: lessons from CheckMate 9ER and IMmotion 151;Khalil;J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Practitioners,2021

4. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis;Xu;BMJ (Clinical research ed).,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis;Health Technology Assessment;2024-08

2. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data;Cancer Immunology, Immunotherapy;2024-01-30

3. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis;International Journal of Urology;2023-10-15

4. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab;Frontiers in Pharmacology;2023-03-03

5. Efficacy and Safety Comparisons of Programmed Cell Death-1 vs Programmed Cell Death Ligand-1 Inhibitors in Patients with Cancer: A Systematic Review and Updated Meta-Analysis;2023